Orthobiologics

SpinalCyte received IRB approval to commence Phase I clinical trials with its CybroCell dermal fibroblast cell product in the treatment...

Zimmer Biomet launched PrimaGen Advanced™ Allograft, an autograft substitute comprising cancellous bone + demineralized cortical bone fibers with verified osteoinductivity....

FDA approved Vericel’s MACI® for the repair of adult symptomatic single or multiple full-thickness cartilage defects of the knee....

Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine’s AlloJoin™ off-the-shelf allogeneic stem cell therapy in...

Study results demonstrated a high rate of clinical success from a combination of Biomatlante’s MBCP+™ synthetic bone graft plus mesenchymal stem...

curasan received FDA 510(k) clearance to market CERASORB Ortho FOAM synthetic bone material for the treatment of bone defects in the...

RTI Surgical’s C-Plus™ PEEK Interbody Fusion system is now indicated for use with allograft, including the company’s map3® cellular allogeneic bone graft. ...

Artoss announced FDA 510(k) clearance to market NanoBone® SBX Putty. ...

Bioventus launched DUROLANE® single-injection joint fluid therapy in Mexico, indicated for treatment of mild to moderate knee osteoarthritis. The product will be...

CMS assigned a unique HCPCS reimbursement code to Fidia Pharma’s HYMOVIS® highly viscoelastic, non-crosslinked hydrogel to treat knee osteoarthritis pain. ...